177Lu-CTR-FAPI for the Treatment of Thyroid Cancer

This is a multi-center, open-label, single-arm, dose-escalation phase I study, aiming to evaluate the safety and efficacy of 177Lu-CTR-FAPI (covalent targeted radioligand-fibroblast activation protein inhibitor), a novel radiopharmaceutical in the treatment of thyroid cancer. The primary endpoint of the study is the safety of 177Lu-CTR-FAPI, and the secondary endpoints include treatment response and dosimetry evaluation.

NCT Number	NCT07438847
Lead Sponsor	SHAOYAN LIU Collaborators: Peking Union Medical College Hospital, Beijing Tsinghua Changgeng Hospital, Navy General Hospital, Beijing
Conditions	Thyroid Cancer
Enrollment	12 participants
Start Date	2026-01-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-27